Impact of minimal inhibitory concentration breakpoints on local cumulative bacterial susceptibility data and antibiotic consumption

详细信息    查看全文

• 作者：Sofia Stokkou (21)
  Ina Tammer (21)
  Stefanie Zibolka (22)
  Christina Grabau (22)
  Gernot Geginat (21)
  
  21. Institut f眉r Medizinische Mikrobiologie und Krankenhaushygiene ; Universit盲tsklinikum Magdeburg ; Leipziger Str. 44 ; 39120 ; Magdeburg ; Germany
  22. Zentralapotheke ; Universit盲tsklinikum Magdeburg ; Leipziger Str. 44 ; 39120 ; Magdeburg ; Germany
  
• 关键词：Antibiotic susceptibility testing ; Minimal inhibitory concentration ; Clinical breakpoints ; EUCAST ; Antibiotic consumption ; Antibiotic stewardship
• 刊名：BMC Research Notes
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：7
• 期：1
• 全文大小：314 KB
• 参考文献：Teil 4: Bewertungsstufen f眉r die Minimale Hemmkonzentration; MHK-Grenzwerte von Antibakteriellen Wirkstoffen. Normung, DDIf eds. (2004) Medizinische Mikrobiologie- Empfindlichkeitspr眉fung von Mikrobiellen Krankheitserregern Gegen Chemotherapeutika. Beuth Verlag GmbH, Berlin, Germany
  1. Breakpoint tables for interpretation of MICs and zone diameters, version 2.0 http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_2.0_120221.pdf
  Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement. M100-S20. CLSI, Wayne, PA, USA
  2. Dellit, TH, Owens, RC, McGowan, JE, Gerding, DN, Weinstein, RA, Burke, JP, Huskins, WC, Paterson, DL, Fishman, NO, Carpenter, CF, Brennan, PJ, Billeter, M, Hooton, TM (2007) Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44: pp. 159-177 CrossRef
  3. Magiorakos, AP, Srinivasan, A, Carey, RB, Carmeli, Y, Falagas, ME, Giske, CG, Harbarth, S, Hindler, JF, Kahlmeter, G, Olsson-Liljequist, B, Paterson, DL, Rice, LB, Stelling, J, Struelens, MJ, Vatopoulos, A, Weber, JT, Monnet, DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: pp. 268-281 CrossRef
  4. F盲rber, J, Moder, KA, Layer, F, Tammer, I, K枚nig, W, K枚nig, B (2008) Extended-spectrum beta-lactamase detection with different panels for automated susceptibility testing and with a chromogenic medium. J Clin Microbiol 46: pp. 3721-3727 CrossRef
  5. Collaborating center for drug statistics methodology. ATC/DDD index 2014 http://www.whocc.no/atcddd/
  6. Jacoby, GA (2005) Mechanisms of resistance to quinolones. Clin Infect Dis 41: pp. S120-S126 CrossRef
  7. Hombach, M, Bloemberg, GV, Bottger, EC (2012) Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of gram-negative bacilli. J Antimicrob Chemother 67: pp. 622-632 CrossRef
  8. Hombach, M, Mouttet, B, Bloemberg, GV (2013) Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC beta-lactamase-producing clinical enterobacteriaceae isolates. J Antimicrob Chemother 68: pp. 2092-2098 CrossRef
  9. Hombach, M, Wolfensberger, A, Kuster, SP, Bottger, EC (2013) Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of gram-negative rods. J Clin Microbiol 51: pp. 2385-2387 CrossRef
  10. Huang, CC, Chen, YS, Toh, HS, Lee, YL, Liu, YM, Ho, CM, Lu, PL, Liu, CE, Chen, YH, Wang, JH, Tang, HJ, Yu, KW, Liu, YC, Chuang, YC, Xu, Y, Ni, Y, Ko, WC, Hsueh, PR (2012) Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among enterobacteriaceae isolates in the Asia-pacific region: results from the study for monitoring antimicrobial resistance trends (SMART), 2002鈥?010. Int J Antimicrob Agents 40: pp. S4-S10 CrossRef
  11. Liu, PY, Shi, ZY, Tung, KC, Shyu, CL, Chan, KW, Liu, JW, Wu, ZY, Kao, CC, Huang, YC, Lin, CF (2014) Antimicrobial resistance to cefotaxime and ertapenem in enterobacteriaceae: the effects of altering clinical breakpoints. J Infect Dev Ctries 8: pp. 289-296 CrossRef
  12. van der Bij, AK, van Dijk, K, Muilwijk, J, Thijsen, SF, Notermans, DW, de Greeff, S, van de Sande-Bruinsma, N (2012) Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia. Clin Microbiol Infect 18: pp. E466-E472 CrossRef
  13. Livermore, DM, Andrews, JM, Hawkey, PM, Ho, PL, Keness, Y, Doi, Y, Paterson, D, Woodford, N (2012) Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?. J Antimicrob Chemother 67: pp. 1569-1577 CrossRef
  14. Tamma, PD, Powers, JH (2013) Do patient data really support the clinical and laboratory standards institute recommendation for lowering third-generation cephalosporin interpretive breakpoints?. Clin Infect Dis 57: pp. 624-625 CrossRef
  15. Thomson, KS (2013) Lowering of Third Generation Cephalosporin Breakpoints. Clin Infect Dis 57: pp. 1663-1664 CrossRef
  16. Marchaim, D, Sunkara, B, Lephart, PR, Gudur, UM, Bhargava, A, Mynatt, RP, Zhao, JJ, Bheemreddy, S, Hayakawa, K, Chopra, T, Dhar, S, Kaye, KS (2012) Extended-spectrum beta-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests. Infect Control Hosp Epidemiol 33: pp. 853-855 CrossRef
  17. Hombach, M, Bottger, EC, Roos, M (2013) The critical influence of the intermediate category on interpretation errors in revised EUCAST and CLSI antimicrobial susceptibility testing guidelines. Clin Microbiol Infect 19: pp. E59-E71 CrossRef
  18. Gagliotti, C, Sarti, M, Sabia, C, Gargiulo, R, Rossolini, GM, Carillo, C, Cassani, C, Cipolloni, AP, Pedna, F, Rossi, MR, Incerti, SS, Testa, G, Venturelli, C, Moro, ML (2011) Accuracy of automated and manual systems for susceptibility testing of pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam. New Microbiol 34: pp. 97-99
  19. Sader, HS, Hsiung, A, Fritsche, TR, Jones, RN (2007) Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of escherichia coli and klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis 57: pp. 341-344 CrossRef
  
• 刊物主题：Biomedicine general; Medicine/Public Health, general; Life Sciences, general;
• 出版者：BioMed Central
• ISSN：1756-0500

文摘

Background The phenotypic antimicrobial susceptibility testing (AST) of bacteria depends on minimal inhibitory concentration breakpoints issued by national and international breakpoint committees. The current study was performed in order to test the influence of different AST standards on local cumulative AST data and on antibiotic consumption. Methods Automated AST was performed with clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and E. faecium. From each species 100 prospectively collected non-duplicate clinical isolates were tested and MIC data were interpreted according to the interpretation standards issued by DIN and EUCAST, respectively. In addition cumulative AST data from clinical isolates and antibiotic consumption were monitored before and after implementation of new EUCAST MIC breakpoints. Results The susceptibility rate of P. aeruginosa against piperacillin and gentamicin, and of C. freundii against piperacillin/tazobactam increased significantly, whereas the susceptibility rates of E. cloacae, S. marcescens, and M. morganii against ciprofloxacin decreased significantly after switching from DIN to EUCAST MIC breakpoints. These changes in the cumulative antibiotic resistance pattern were reflected by enhanced consumption of piperacillin/tazobactam after implementation of EUCAST MIC breakpoints. Conclusions These data show that changes of AST breakpoints have a significant influence on local cumulative AST data and on antibiotic consumption.